Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00086333 | FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma | PHASE2 | COMPLETED | 30 | — | — | Jul 1, 2004 | Dec 1, 2005 | Oct 24, 2011 | 4 | United States |
| Name | Type | Description |
|---|---|---|
| SGN-15, Docetaxel | DRUG | - |
Inclusion Criteria: * Patients with pathologically confirmed stage IIIB or IV NSCLC with a minimum of 1 measurable baseline target lesion who have received no prior chemotherapy for metastatic disease and are not eligible for combined modality therapy with curative intent * Patients must have an EC...